Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
GAITHERSBURG, Md., Jan. 15, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Henrietta Ukwu, M.D., FACP, FRAPS, to the position of Senior Vice President, Chief Regulatory and Quality Officer. In this newly created role, Dr. Ukwu will lead global regulatory strategy and execution as well as the quality assurance function for the company’s development-stage vaccine candidates, including its recombinant protein-based COVID-19 candidate vaccine, NVX-CoV2373.
“Dr. Ukwu brings extensive regulatory affairs and quality expertise and leadership experience at precisely the right time for Novavax, as we advance toward data readouts and regulatory submissions in 2021,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “We welcome
Follow the science and other principles of Biden s pandemic response plan
Two Bloomberg School of Public Health alums now members of President-elect Biden s coronavirus task force share the incoming administration s strategies for fighting the COVID-19 pandemic By Katie Pearce / Published Jan 15, 2021
Entering the White House at the height of a global pandemic, President-elect Joe Biden s administration plans to respond by ramping up and simplifying the vaccination process, tackling equity issues, and, above all, following the science, according to two members of Biden s COVID-19 task force. From vaccines to therapeutics, to diagnostics, to other public health recommendations, everything is going to be informed by the science, said task force member and infectious disease specialist Céline Gounder during a webcast hosted by the Johns Hopkins Bloomberg School of Public Health on Thursday.
Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
January 14, 2021 16:05 ET | Source: NextCure NextCure Beltsville, Maryland, UNITED STATES
BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr. Myint will oversee the clinical development of key products in NextCure’s product pipeline, including NC318, a first-in-class immunomedicine, targeting Siglec-15 (S15), and NC410, recombinant LAIR-2 fusion protein designed to block immune suppression mediated by the immune modulator LAIR-1. Prior to joining NextCure, Dr. Myint held senior roles at both Celgene (a Bristol Myers Squibb Company) and NexImmune Inc.
Feeling Left Out: Private Practice Doctors, Patients Wonder When It s Their Turn for Vaccine canadianinquirer.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from canadianinquirer.net Daily Mail and Mail on Sunday newspapers.
Crystal Denlinger Named Chief Scientific Officer for National Comprehensive Cancer Network
PLYMOUTH MEETING, Pa., Jan. 14, 2021 /PRNewswire/ The National Comprehensive Cancer Network (NCCN
)-an alliance of leading cancer centers-today announced the appointment of
Crystal S. Denlinger, MD, FACP, to the newly-created role of Senior Vice President, Chief Scientific Officer. In this position, Dr. Denlinger will help to steer strategic direction for the nonprofit as well as oversee the NCCN Oncology Research Program (ORP). Her duties will also involve providing input into NCCN s clinical information program, including the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
), as well as various continuing education activities.